Tempus And Remix Therapeutics Collaborate To Expanded Data And Sequencing
Portfolio Pulse from Benzinga Newsdesk
Tempus AI, Inc. (NASDAQ:TEM) has expanded its collaboration with Remix Therapeutics to include next-generation sequencing support for Remix's Phase I trial for REM-422. The partnership leverages Tempus' multimodal data and analytics platform to target specific cohorts such as Adenoid Cystic Carcinoma and Acute Myeloid Leukemia.
July 30, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tempus AI, Inc. (NASDAQ:TEM) has expanded its collaboration with Remix Therapeutics to include next-generation sequencing support for Remix's Phase I trial for REM-422. This partnership leverages Tempus' multimodal data and analytics platform to target specific cohorts such as Adenoid Cystic Carcinoma and Acute Myeloid Leukemia.
The expanded collaboration with Remix Therapeutics is likely to positively impact Tempus AI's stock in the short term. The partnership enhances Tempus' role in precision medicine and next-generation sequencing, which are critical growth areas in biotechnology.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100